| Date | Quarter | Session | EPS (est → actual) | Revenue (est → actual) |
|---|---|---|---|---|
| Nov 4, 2026Next | Q3 2026 | — | 5.08 | 73.7 B |
Aug 24, 2026
Novo Nordisk (NVO) may be bottoming as LLY share losses stabilize; trading ~15x forward earnings with catalysts like Wegovy pill & CagriSema.
Aug 22, 2026
Eli Lilly (LLY) leads the global obesity drug market vs Novo Nordisk as competition heats up.
Aug 21, 2026
Novo Nordisk A/S stays a Buy as oral Wegovy surges and GLP-1 pipeline strengthens; attractive 2028 P/E suggests upsideâclick to read the NVO stock outlook now.
Aug 19, 2026
https://www.wsj.com/health/pharma/novo-nordisk-starts-testing-lower-doses-of-its-wegovy-weight-loss-pills-8896fec2
Aug 12, 2026
Aug 11, 2026
Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly basal injections from seven to one per week1Awiqli® will be available at over 70,000
Aug 7, 2026
There have been some puzzling results in connecting inflammation with cardiovascular disease, but Novo Nordisk's recent trial result is by far the biggest hit the hypothesis has ever taken.
Novo Nordisk A/S gets a Sell rating as profits slide, guidance weakens, and competition rises vs Eli Lilly. Click for this NVO stock update and a look at earnings.
Aug 6, 2026
Novo Nordisk A/S beat Q2 revenue and EPS, raised guidance again, and still dipped. Click for this NVO stock update and see if it is right for you.
A Dutch court has banned sales of an unapproved compounded semaglutide nasal spray following a legal victory for Novo Nordisk.
Aug 5, 2026
Novo Nordisk A/S (NOVO:CA) Q2 2026 Earnings Call August 5, 2026 7:00 AM EDTCompany ParticipantsMichael Novod - Senior VP & Head of Investor...
2026-08-05. The following slide deck was published by Novo Nordisk A/S in conjunction with their 2026 Q2 earnings call.
Novo Nordisk Q2 results: obesity drug growth (Wegovy pill) offsets pricing pressure. Shares fell 6%, but DCF suggests 25% upside. Click for more on NVO stock.
Aug 4, 2026
Novo Nordisk (NYSE:NVO) reported quarterly earnings of $0.96 per share which beat the analyst consensus estimate of $0.81 by 18.52 percent. This is a 5.49 percent increase over earnings of $0.91 per share from the same
Novo Nordisk raises 2026 guidance as Wegovy pill tops 5 million U.S. prescriptions, but stock falls despite higher GLP-1 sales expectations.
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916590
